MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 03-09-2026
Anixa Biosciences Cash Conversion Cycle 2011-2026 | ANIX
Annual Cash Conversion Cycle Anixa Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 275 | - | - | - | -1.19 K | -276 | -1.68 K | -787 | -37.5 | -59.4 | -443 | -28.7 K | -4.01 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 275 | -28.7 K | -3.69 K |
Quarterly Cash Conversion Cycle Anixa Biosciences
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | 55.6 | 4.18 | - | - | - | - | - | - | - | - | - | - | - | - | 24.3 | 24.3 | 12.1 | - | 25.2 | 38.6 | - | - | 27.8 | 27.8 | - | - | - | - | - | 0.22 | - | - | - | - | 15.9 | 30.7 | 16.5 | 3.75 K | - | - | - | 0.71 | 912 | -46.7 | - | - | -11.5 | -29.9 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.75 K | -46.7 | 257 |
Cash Conversion Cycle of other stocks in the Diagnostics research industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
50.2 | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
36.1 | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
-38.7 | - | -6.19 % | $ 10.5 M |  USA |
 |
Bioventus
BVS
|
224 | $ 8.99 | 1.35 % | $ 599 M | USA |
 |
CareDx, Inc
CDNA
|
51.5 | $ 17.6 | 1.62 % | $ 938 M | USA |
 |
Charles River Laboratories International
CRL
|
65 | $ 153.71 | 1.14 % | $ 7.62 B | USA |
 |
Castle Biosciences
CSTL
|
45.9 | $ 25.9 | 0.27 % | $ 719 M | USA |
 |
Accelerate Diagnostics
AXDX
|
364 | - | -61.36 % | $ 2.46 M | USA |
 |
DexCom
DXCM
|
134 | $ 67.32 | 1.48 % | $ 26.3 B | USA |
 |
Global Cord Blood Corporation
CO
|
184 | - | - | $ 399 M |  China |
 |
Genetic Technologies Limited
GENE
|
11 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
142 | - | 0.12 % | $ 80.1 M | China |
 |
Exact Sciences Corporation
EXAS
|
42.5 | $ 103.94 | 0.09 % | $ 19.6 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
1.21 K | - | - | $ 10.7 B | USA |
 |
Fulgent Genetics
FLGT
|
42.4 | $ 15.43 | 3.21 % | $ 467 M | USA |
|
Biodesix
BDSX
|
41.7 | $ 16.59 | -4.05 % | $ 2.15 B | USA |
 |
Guardant Health
GH
|
79.6 | $ 88.75 | 1.8 % | $ 11.1 B | USA |
 |
Danaher Corporation
DHR
|
77.5 | $ 195.21 | 2.0 % | $ 139 B | USA |
 |
Biocept
BIOC
|
78.1 | - | -13.05 % | $ 7.29 M | USA |
 |
Heska Corporation
HSKA
|
138 | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
104 | - | -20.0 % | $ 1.06 M | USA |
 |
ICON Public Limited Company
ICLR
|
62 | $ 100.49 | 2.95 % | $ 8.29 B |  Irlanda |
 |
Illumina
ILMN
|
142 | $ 120.84 | 1.31 % | $ 19.2 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
39.5 | $ 198.61 | -0.17 % | $ 22 B | USA |
 |
QIAGEN N.V.
QGEN
|
122 | - | - | $ 10.6 B |  Niderland |
 |
IQVIA Holdings
IQV
|
73.9 | $ 168.43 | 2.15 % | $ 29 B | USA |
 |
Agilent Technologies
A
|
111 | $ 112.75 | 0.82 % | $ 34.3 B | USA |
 |
BioNano Genomics
BNGO
|
225 | $ 1.13 | 1.8 % | $ 1.44 M | USA |
 |
DarioHealth Corp.
DRIO
|
207 | $ 8.75 | 3.92 % | $ 248 M |  Israel |
 |
Lantheus Holdings
LNTH
|
97.3 | $ 80.45 | 2.48 % | $ 5.43 B | USA |
 |
Chembio Diagnostics
CEMI
|
111 | - | 0.22 % | $ 16.8 M | USA |
 |
Co-Diagnostics
CODX
|
299 | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Medpace Holdings
MEDP
|
50.4 | $ 455.15 | 0.33 % | $ 13.1 B | USA |
 |
Motus GI Holdings
MOTS
|
3.45 K | - | -34.28 % | $ 263 K | Israel |
 |
DermTech
DMTK
|
66.7 | - | -11.32 % | $ 2.94 M | USA |
 |
Mettler-Toledo International
MTD
|
66.4 | $ 1 206.72 | 0.63 % | $ 24.9 B |  Schweiz |
 |
NeoGenomics
NEO
|
82.4 | $ 8.27 | 0.36 % | $ 1.06 B | USA |
 |
Neogen Corporation
NEOG
|
150 | $ 9.27 | 1.76 % | $ 2.01 B | USA |
 |
Enzo Biochem
ENZ
|
154 | - | -8.98 % | $ 14.8 K | USA |
 |
National Research Corporation
NRC
|
29.4 | $ 17.73 | 1.9 % | $ 397 M | USA |
 |
Natera
NTRA
|
81.5 | $ 198.38 | 0.35 % | $ 19.5 B | USA |
 |
Invitae Corporation
NVTA
|
299 | - | - | $ 21.2 M | USA |
 |
Myriad Genetics
MYGN
|
49.3 | $ 4.78 | 4.14 % | $ 443 M | USA |
 |
OPKO Health
OPK
|
242 | $ 1.19 | - | $ 826 M | USA |